Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.58 |
| ▸ | PPARA | Q07869 | 15/20 | 0.58 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5430617 | 0.92 | PPARG (0.57) | PPARGPPARALMNA | |
| SCHEMBL6073111 | 0.86 | PPARA (0.52) | PPARGPPARASLC2A1 | |
| SCHEMBL6073222 | 0.85 | PPARA (0.48) | PPARGPPARASLC2A1 | |
| SCHEMBL5429608 | 0.84 | PPARG (0.47) | PPARGPPARALMNASLC2A1 | |
| SCHEMBL6073127 | 0.82 | PPARA (0.52) | PPARGPPARALMNASLC2A1 | |
| SCHEMBL6073264 | 0.82 | PPARA (0.47) | PPARGPPARALMNASLC2A1 | |
| SCHEMBL6073214 | 0.81 | PPARA (0.51) | PPARGPPARASLC2A1 | |
| SCHEMBL6073105 | 0.81 | PPARG (0.59) | PPARGPPARASLC2A1 | |
| SCHEMBL6073154 | 0.81 | PPARA (0.43) | PPARGPPARALMNASLC2A1 | |
| SCHEMBL6073206 | 0.81 | PPARA (0.54) | PPARGPPARASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | claimed |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CYP46A1, DHCR7, NPC1L1 | PPARG 615/4885PPARA 990/4885MEP1B 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.